(Reuters) -Summit Therapeutics ( SMMT ) and AstraZeneca ( AZN ) are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Under the potential deal, AstraZeneca ( AZN ) could license Summit's experimental lung-cancer treatment, ivonescimab, the report said.

Summit did not immediately respond to Reuters request seeking comment, while an AstraZeneca ( AZN ) spokesperson declined to comment.

A deal between the companies could include an upfront payment of several billion dollars to Summit and milestone payments later on, Bloomberg News said.